#LCSM Chat Topic 4-Mar-2021: Liquid Bx—It pays to be vein

Cancer diagnosis for solid tumors has traditionally relied on biopsied tumor tissue. For patients already diagnosed with lung cancer, blood-based liquid biopsies are increasingly being used to look for bits of tumor proteins or DNA that can help identify suitable treatment options. The US FDA has even approved two liquid biopsies that can detect actionable mutations in lung cancer. However, there are several liquid biopsies technologies, and researchers are exploring whether those could be used to answer other questions in the cancer space, such as: Early detection: Is cancer present? If so,… Read More

#LCSM Chat Topic 4-Feb-2021: “#WCLC20 from the comfort of your own home”

Well, we finally moved on to 2021, only to be thrust seemingly backward to #WCLC20!  The incredible content from #WCLC20 was certainly worth the wait.  Although we didn’t get to experience the meeting live together in Singapore, a new virtual platform brought it all to us in the comfort of our own homes. Several topics discussed at #WCLC20 stood out and deserve a deeper dive within the #LCSM community. There was a great deal of buzz about the TALENT study from Taiwan which looked at lung cancer screening in never or light… Read More

#LCSM Chat Topic 10/01/2020: Crazy year, crazy progress–#lungcancer at #ESMO20

Without a doubt, 2020 has been overwhelming for many reasons.  Perhaps lost among the bigger news cycles of #COVID19, the presidential race, and now the Supreme Court, has been the staggering progress that has been made in #LungCancer through the year.  There has been a remarkable run of FDA approvals, including drugs for non-small cell lung cancer (NSCLC) with RET rearrangements and MET exon 14 mutations, new first line therapies for NSCLC with EGFR mutations and ALK rearrangements, and new first line immunotherapy options for a variety of lung cancer scenarios.  This… Read More